Back to top
more

Becton, Dickinson and Company (BDX)

(Delayed Data from NYSE)

$237.84 USD

237.84
1,032,669

+0.54 (0.23%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

STERIS Focuses on Expanding Core Business, Competition Rife

by Zacks Equity Research

STERIS (STE) pursues six acquisitions in the first nine months of fiscal 2018.

    Here's Why You Should Invest in LabCorp (LH) Stock Right Now

    by Zacks Equity Research

    Strong guidance and Covance Drug Development's sturdy growth raise investors optimism on LabCorp (LH).

      Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat

      by Zacks Equity Research

      Henry Schein's (HSIC) strong share gains in the North American and overseas markets along with solid revenues raise optimism.

        AmerisourceBergen (ABC) Jumps: Stock Rises 9.3%

        by Zacks Equity Research

        AmerisourceBergen (ABC) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

          GNC Holdings to Boost International Business With New Deals

          by Zacks Equity Research

          GNC Holdings (GNC) adopts initiatives to boost contributions from international business with strong focus on China.

            GNC Holdings (GNC) Tops Q4 Earnings, Lags Revenue Estimates

            by Zacks Equity Research

            Despite sluggish performance by manufacturing/wholesale segments, GNC Holdings (GNC) witnesses revenue growth in Q4.

              CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat

              by Zacks Equity Research

              A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.

                Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View

                by Zacks Equity Research

                Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.

                  STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up

                  by Zacks Equity Research

                  STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.

                    CAH vs. HOLX: Which Will Fare Better This Earnings Season?

                    by Zacks Equity Research

                    Here we look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.

                      Becton (BDX) Beats on Q1 Earnings and Revenues Estimates

                      by Zacks Equity Research

                      Becton, Dickinson and Company (BDX) delivers strong performance in Q1 on the back strong segmental performance.

                        Medical Product Stocks' Earnings on Feb 6: BDX, LH & More

                        by Zacks Equity Research

                        Here we take a look at the major factors that are likely to influence the earnings results of a few MedTech bigwigs.

                          Should You Buy Becton, Dickinson (BDX) Ahead of Earnings?

                          by Zacks Equity Research

                          Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                            Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat

                            by Zacks Equity Research

                            Quality Systems (QSII) benefits from solid bookings and acquisitions in Q3.

                              What's in Store for Becton, Dickinson (BDX) in Q1 Earnings?

                              by Zacks Equity Research

                              Despite solid prospects in the emerging markets, Becton, Dickinson (BDX) is likely to witness sluggishness in BD Medical and BD Life Sciences in Q1.

                                Becton, Dickinson (BDX), Bard Receive Regulatory Nod in China

                                by Zacks Equity Research

                                Favorable tidings on the regulatory front have boosted Becton, Dickinson and Company (BDX) lately. After the closure of the deal, the company will establish a new business segment.

                                  Becton, Dickinson (BDX) a Step Closer to Bard Acquisition

                                  by Zacks Equity Research

                                  Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.

                                    Merit Medical Deserves a Place in Your Portfolio: Here's Why

                                    by Zacks Equity Research

                                    A slew of bolt-on acquisitions leverages Merit Medical (MMSI) to drive inorganic growth.

                                      The Zacks Analyst Blog Highlights: Morris, EOG Resources, Becton, Dickinson, Sirius XM and ABB

                                      by Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Morris, EOG Resources, Becton, Dickinson, Sirius XM and ABB

                                        Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak

                                        by Zacks Equity Research

                                        Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.

                                          Becton, Dickinson Focuses on Medication Management, Stock Up

                                          by Zacks Equity Research

                                          Management at Becton, Dickinson and Company (BDX) has been focusing on strengthening its portfolio for long.

                                            Becton Dickinson (BDX) in Focus: Stock Moves 7.7% Higher

                                            by Zacks Equity Research

                                            Becton Dickinson (BDX) saw its shares rise nearly 8% on the day after the company posted better-than-expected third-quarter results.

                                              Becton (BDX) Tops Q4 Earnings and Revenues Estimates

                                              by Zacks Equity Research

                                              Becton, Dickinson???s adjusted earnings of $2.40 per share beat the Zacks Consensus Estimate by 2 cents and increased from $2.12 posted in the year-ago quarter.

                                                Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?

                                                by Zacks Equity Research

                                                Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.

                                                  Becton, Dickinson (BDX) Tops Q3 Earnings, Misses On Revenues

                                                  by Zacks Equity Research

                                                  Impressive results in Becton, Dickinson's (BDX) medical segment reflect strong performance in the Medication and Procedural Solutions, Diabetes Care and Pharmaceutical Systems units.